MarketPulse

growth portfolio

4 articles
The Motley FoolThe Motley Fool··Eric Volkman

Bristol Myers Squibb Surges on Strong Q1 Earnings Beat, Growth Portfolio Delivers

Bristol Myers Squibb surges 5% after beating Q1 earnings expectations, with growth portfolio sales up 12% and full-year guidance reaffirmed.
BMYCELGrprofitabilityrevenue beat
BenzingaBenzinga··Vandana Singh

Bristol-Myers Squibb Surges on Strong Q1 Earnings Beat Across Portfolio

Bristol-Myers Squibb stock jumped 4.44% after Q1 earnings beat expectations, with revenue up 3% and growth portfolio surging 12% year-over-year.
BMYCELGrrevenue growthearnings beat
The Motley FoolThe Motley Fool··Jack Delaney

Bristol Myers Squibb Offers Dividend Appeal, But Patent Cliff Looms Large

Bristol Myers Squibb trades at attractive 9.5x forward P/E with 4.2% yield and 17 years of dividend hikes, but faces revenue declines and patent expiration risks.
BMYCELGrJNJMRKvalue investingdividend stocks
The Motley FoolThe Motley Fool··Jennifer Saibil

Semiconductor and Tech Leaders Positioned for Long-Term Growth

TSM, Apple, and SanDisk positioned for long-term growth through AI adoption, device installed base, and storage demand expansion respectively.
NVDASNDKAMZNGOOGGOOGL+2artificial intelligencesemiconductor